B-type natriuretic peptides: Looking to the future

Annals of Medicine

Volumn 43, Issue 3, 2011, Pages 188-197

  Troughton, Richard W ^a   Lewis, Lynley K ^a   Yandle, Timothy G ^a   Pemberton, Christopher J ^a   Nicholls, M Gary ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Atrial natriuretic peptide; B type natriuretic peptide; diabetes mellitus; heart failure; hypertension; myocardial infarction; renal failure; signal peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LCZ 696; METALLOPROTEINASE INHIBITOR; OMAPATRILAT; PLACEBO; RENIN INHIBITOR; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE MARKER; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RENAL REPLACEMENT THERAPY; REVIEW; THALASSEMIA;

ANIMALS; ATRIAL NATRIURETIC FACTOR; DYSPNEA; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 79953881826     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2010.526630     Document Type: Review

References (71)

1. Wu AHB, Jaffe AS, Apple FS, Jesse RL, Francis GL, Morrow DA, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem. 2007;53:2086-96. (Pubitemid 350197291)
2. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647-54. (Pubitemid 38364623)
3. Mueller C, Laule-Kilian K, Schindler C, Klima T, Frana B, Rodriguez D, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med. 2006;166:1081-7. (Pubitemid 43765179)
4. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-7. (Pubitemid 34764819)
5. Siebert U, Januzzi JJL, Beinfeld MT, Cameron R, Gazelle GS. Cost-effectiveness of using N-terminal pro-brain natriu-retic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol. 2006;98:800-5. (Pubitemid 44301027)
6. Moe GW, Howlett J, Januzzi JL, Zowall H; Canadian Multicenter Improved Management of Patients With Congestive Heart Failure Study I. N-terminal pro-B-type natriu-retic peptide testing improves the management of patients with suspected acute heart failure: Primary results of the Canadian prospective randomized multicenter IMPROVE-CHF Study. Circulation. 2007;115:3103-10. (Pubitemid 46956499)
7. Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: A randomized, controlled trial. J Am Coll Cardiol. 2003;42:1793-800. (Pubitemid 37433660)
8. Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail. 2004;6:63-70. (Pubitemid 38169606)
9. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 1994;343:440-4. (Pubitemid 24059585)
10. Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA. 2005;294:1944-56. (Pubitemid 41464696)
11. Mogelvang R, Goetze JP, Schnohr P, Lange P, Sogaard P, Rehfeld JF, et al. Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. J Am Coll Cardiol. 2007;50:1694-701. (Pubitemid 47562682)
12. Rogers RK, Stoddard GJ, Greene T, Michaels AD, Fernandez G, Freeman A, et al. Usefulness of adjusting for clinical covariates to improve the ability of B-type natriuretic peptide to distinguish cardiac from noncardiac dyspnea. Am J Cardiol. 2009;104:689-94.
13. Anderson JV, Woodruff PW, Bloom SR. The effect of treatment of congestive heart failure on plasma atrial natriuretic peptide concentration: a longitudinal study. Br Heart J. 1988;59:207-11. (Pubitemid 18045123)
14. Stevenson LW, Dracup KA, Tillisch JH. Effi cacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation. Am J Cardiol. 1989;63:461-4. (Pubitemid 19065323)
15. Steimle AE, Stevenson LW, Chelimsky-Fallick C, Fonarow GC, Hamilton MA, Moriguchi JD, et al. Sustained hemo-dynamic effi cacy of therapy tailored to reduce fi lling pressures in survivors with advanced heart failure. Circulation. 1997;96:1165-72. (Pubitemid 27344219)
16. Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemody-namic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 1999;138:1126-32.
17. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-30. (Pubitemid 30172933)
18. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials. Am Heart J. 2009;158:422-30.
19. Pfi sterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided vs symptom-guided heart failure therapy: The trial of intensifi ed vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) Randomized Trial. JAMA. 2009;301:383-92.
20. Lainchbury JG, Troughton RW, Strangman KM, Framp-ton CM, Pilbrow A, Yandle TG, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2010; 55:53-60.
21. Kosiborod M, Lichtman JH, Heidenreich PA, Normand SL, Wang Y, Brass LM, et al. National trends in outcomes among elderly patients with heart failure. Am J Med. 2006;119:616. e1-16.e7.
22. Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010;170:507-14.
23. Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multi-disciplinary care in chronic heart failure: A 3-arm, prospective, randomized pilot study. J Am Coll Cardiol. 2010;55:645-53.
24. Schou M, Gustafsson F, Videbaek L, Markenvard J, Ulriksen H, Ryde H, et al. Design and methodology of the NorthStar study: NT-proBNP stratifi ed follow-up in outpatient heart failure clinics - A randomized Danish multicenter study. Am Heart J. 2008;156:649-55.
25. Paterna S, Parrinello G, Cannizzaro S, Fasullo S, Torres D, Sarullo FM, et al. Medium term effects of different dosage of diuretic, sodium, and fl uid administration on neurohor-monal and clinical outcome in patients with recently compensated heart failure. Am J Cardiol. 2009;103:93-102.
26. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-69. (Pubitemid 37337595)
27. Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: Effects on the cardiovascular system. Circulation. 2007; 116:85-97. (Pubitemid 47016250)
28. Dastoor H, Bernieh B, Boobes Y, Abouchacra S, Eltayeb E, Elhuda MN, et al. Plasma BNP in patients on maintenance haemodialysis: a guide to management? J Hypertens. 2005;23:23-8. (Pubitemid 40128974)
29. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001;12:1508-15. (Pubitemid 32666334)
30. Gutierrez OM, Tamez H, Bhan I, Zazra J, Tonelli M, Wolf M, et al. N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. Clin Chem. 2008;54:1339-48.
31. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation. 2009;120:2177-87.
32. deFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL. Dynamic cardiovascular risk assessment in elderly people: The role of repeated N-terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol. 2010; 55:441-50.
33. Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet. 2002;359:1430-2. (Pubitemid 34442390)
34. Bhalla MA, Chiang A, Epshteyn VA, Kazanegra R, Bhalla V, Clopton P, et al. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2004;44:1047-52. (Pubitemid 39165140)
35. G æ de P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia. 2005;48: 156-63.
36. Betti I, Castelli G, Barchielli A, Beligni C, Boscherini V, De Luca L, et al. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF Study. J Card Fail. 2009; 15:377-84.
37. Andreadis EA, Georgiopoulos DX, Tzavara CK, Katsanou PM, Fragouli EG, Mavrokefalou EM, et al. Plasma brain natriuretic peptide: a biochemical marker of effective blood pressure management? J Hypertens. 2009;27:425-32.
38. Carr SJ, Bavanandan S, Fentum B, Ng L. Prognostic potential of brain natriuretic peptide (BNP) in predialysis chronic kidney disease patients. Clin Sci. 2005;109:75-82. (Pubitemid 40943036)
39. Chrysohoou C, Greenberg M, Pitsavos C, Panagiotakos DB, Ladis V, Barbetseas J, et al. Diastolic function in young patients with beta-thalassemia major: An echocardiographic study. Echocardiography. 2006;23:38-44.
40. Kremastinos DT, Hamodraka E, Parissis J, Tsiapras D, Dima K, Maisel A. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in β -thalassemia major. Am Heart J. 2010;159:68-74.
41. Ribeiro ALP, dos Reis AM, Barros MVL, de Sousa MR, Rocha ALL, Perez AA, et al. Brain natriuretic peptide and left ventricular dysfunction in Chagas'disease. Lancet. 2002;360:461-2. (Pubitemid 34880146)
42. Moreira MC, Wang Y, Heringer-Walther S, Wessel N, Walther T. Prognostic value of natriuretic peptides in Chagas'disease: A head-to-head comparison of the 3 natriuretic peptides. Congest Heart Fail. 2009;15:75-81.
43. Cuthbertson BH, Croal BL, Rae D, Gibson PH, McNeilly JD, Jeffrey RR, et al. N-terminal pro-B-type natriuretic pep-tide levels and early outcome after cardiac surgery: a prospective cohort study. Br J Anaesth. 2009;103:647-53.
44. Attaran S, Sherwood R, Desai J, Langworthy R, Mhandu P, John L, et al. Brain natriuretic peptide a predictive marker in cardiac surgery. Interact Cardiovasc Thorac Surg. 2009; 9:662-6.
45. Karthikeyan G, Moncur RA, Levine O, Heels-Ansdell D, Chan MTV, Alonso-Coello P, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol. 2009;54:1599-606.
46. Choi J-H, Cho DK, Song Y-B, Hahn J-Y, Choi S, Gwon H-C, et al. Perioperative NT-proBNP and CRP predict peri-operative major cardiovascular events in non-cardiac surgery. Heart. 2010;96:56-62.
47. Gill D, Seidler T, Troughton RW, Yandle TG, Frampton CM, Richards M, et al. Vigorous response in plasma N-terminal pro-brain natriuretic peptide (NT-BNP) to acute myocardial infarction. Clin Sci. 2004;106:135-9. (Pubitemid 38223431)
48. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014-21.
49. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, et al. Multimarker approach to risk stratifi cation in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760-3. (Pubitemid 34408881)
50. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myo-cardial infarction. Circulation. 2008;117:1936-44. (Pubitemid 351543469)
51. Khan SQ, Narayan H, Ng KH, Dhillon OS, Kelly D, Quinn P, et al. N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome. Clin Sci. 2009;117:31-9.
52. Kragelund C, Gronning B, Kober L, Hildebrandt P, Stef-fensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352:666-75. (Pubitemid 40239214)
53. Bibbins-Domingo K, Gupta R, Na B, Wu AHB, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297:169-76. (Pubitemid 46089733)
54. Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol. 2007;50:205-14. (Pubitemid 47031568)
55. Staub D, Nusbaumer C, Zellweger MJ, Jonas N, Wild D, Pfisterer ME, et al. Use of B-type natriuretic peptide in the detection of myocardial ischemia. Am Heart J. 2006;151: 1223-30. (Pubitemid 43866600)
56. Sanchis J, Bosch X, Bod í V, N ú ñ ez J, Doltra A, Heras M, et al. Randomized comparison between clinical evaluation plus N-terminal pro-B-type natriuretic peptide versus exercise testing for decision making in acute chest pain of uncertain origin. Am Heart J. 2010;159:176-82.
57. Hawkridge AM, Heublein DM, Bergen HR, Cataliotti A, Burnett JC, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA. 2005;102:17442-7. (Pubitemid 41740885)
58. Niederkofl er EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, et al. Detection of endogenous B-type natriu-retic peptide at very low concentrations in patients with heart failure. Circ Heart Fail. 2008;1:258-64.
59. Lainchbury JG, Richards AM, Nicholls MG, Hunt PJ, Ikram H, Espiner EA, et al. The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension. 1997;30:398-404. (Pubitemid 27446099)
60. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246-53. (Pubitemid 30490392)
61. Topol EJ. Nesiritide - not verifi ed. N Engl J Med. 2005; 353:113-6.
62. Nakanishi M, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, et al. Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice. Hypertension. 2005;46:441-7. (Pubitemid 41099182)
63. Hillock RJ, Frampton CM, Yandle TG, Troughton RW, Lainchbury JG, Richards AM. B-type natriuretic peptide infusions in acute myocardial infarction. Heart. 2008;94:617-22. (Pubitemid 351580137)
64. Chen HH, Martin FL, Gibbons RJ, Schirger JA, Wright RS, Schears RM, et al. Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart. 2009;95:1315-9.
65. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al. Human atrial natriuretic peptide and nic-orandil as adjuncts to reperfusion treatment for acute myo-cardial infarction (J-WIND): two randomised trials. Lancet. 2007;370:1483-93. (Pubitemid 47625560)
66. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC Jr. Design, synthesis, and actions of a novel chimeric natri-uretic peptide: CD-NP. J Am Coll Cardiol. 2008;52:60-8. (Pubitemid 351852935)
67. Pan S, Chen HH, Dickey DM, Boerrigter G, Lee C, Kleppe LS, et al. Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci USA. 2009;106:11282-7.
68. Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, et al. Oral human brain natriuretic peptide activates cyclic guanosine 3 ',5'-monophosphate and decreases mean arterial pressure. Circulation. 2005;112:836-40. (Pubitemid 41170069)
69. Therrien J-P, Kim SM, Terunuma A, Qin Y, Tock CL, Pf ü tzner W, et al. A gene therapy approach for long-term normalization of blood pressure in hypertensive mice by ANP-secreting human skin grafts. Proc Natl Acad Sci USA. 2010;107:1178-83.
70. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin 11 receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255-66.
71. Siriwardena M, Kleffmann T, Ruygrok P, Cameron VA, Yandle TG, Nicholls MG, et al. B-type natriuretic peptide signal peptide circulates in human blood. Circulation. 2010; 122:255-64.